Santosh Gautam

Santosh Gautam

Auto-generated profile, based on publicly available information

Santosh Gautam

Johnson & Johnson

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Pain Medicine
Verified
Journal Article
Open access
PDF file
SGSantosh Gautam
Santosh Gautam
LFLuisa Franzini
Luisa Franzini
OMOsama I. Mikhail
Osama I. Mikhail
WCWenyaw Chan
Wenyaw Chan
BTBarbara J. Turner
Barbara J. Turner
Objective. To examine associations of opioid analgesic dose with quality of care for diabetes mellitus.Design. Longitudinal statewide cohort.Subjects.

10 December 2020 in Future Oncology
Verified
Journal Article
Closed access
JLJunji Lin
Junji Lin
SGSantosh Gautam
Santosh Gautam
NHNan Hu
Nan Hu
GAGboyega Adeboyeje
Gboyega Adeboyeje
SKSumesh Kachroo
Sumesh Kachroo
Background: Real-world data are lacking on patients with small-cell lung cancer (SCLC) with extensive-stage SCLC (eSCLC) and poor performance status (PS). Patients & methods: Eligible patients diag... Lay abstract Real-world data are lacking on patients with small-cell lung cancer (SCLC) that has spread, called extensive-stage SCLC (eSCLC), and who have a poor level of functioning, called impair...

9 June 2023 in Future Oncology
Verified
Journal Article
Closed access
SGSantosh Gautam
Santosh Gautam
SYShweta Yeola
Shweta Yeola
ANAkash Nahar
Akash Nahar
ESEric M Sarpong
Eric M Sarpong
JPJennifer Prescott
Jennifer Prescott
HSHelmneh M Sineshaw
Helmneh M Sineshaw
Aim: Unfavorable prognostic factors among classical Hodgkin lymphoma (cHL) patients in the real-world setting have yet to be fully characterized. Methods: In this retrospective study using the Conc... Plain language summary - Assessment of risk factors in patients with classical Hodgkin lymphoma in a real-world setting What is this article about? Lymphoma is a type of blood cancer that develops ...

6 October 2022 in Future Oncology
Verified
Journal Article
Open access
ANAlnecia R Nisbett
Alnecia R Nisbett
XYXiaoqin Yang
Xiaoqin Yang
PSPatrick Squires
Patrick Squires
SGSantosh Gautam
Santosh Gautam
KDKaushal Desai
Kaushal Desai
ANAkash Nahar
Akash Nahar
Aim: Limited real-world data exist on treatment patterns and clinical outcomes for patients with relapsed/refractory (R/R) classical Hodgkin's lymphoma (cHL). Methods: This study used the ConcertAI...

15 February 2022 in Cancer Research
Verified
Journal Article
Open access
KKKevin M Kalinsky
Kevin M Kalinsky
MKMegan Kruse
Megan Kruse
ESEmily Nash Smyth
Emily Nash Smyth
CGClaudia M Guimaraes
Claudia M Guimaraes
SGSantosh Gautam
Santosh Gautam
LBLee Bowman
Lee Bowman
Background: Cyclin-dependent kinase 4 and 6 inhibitors (CDK4 & 6i) provide significant benefit for patients (pts) with HR+, HER2- MBC, however, clinical questions remain regarding the optimal sequence (seq) of treatments (tx). Prior analyses of real world (rw) abemaciclib indicate up to 50% of pts have had prior palbociclib or ribociclib for MBC and published studies regarding seq and non-seq tx outcomes have had limited sample sizes. To our knowledge, the current study represents the largest rw analysis of CDK4 & 6i tx seq to date. Methods: US electronic medical records were retrospectively analyzed from the ConcertAI Oncology Dataset. Pts received abemaciclib and ≥ 1 other systemic tx line for HR+, HER2- MBC; the study period was 11/1995 (date of first MBC dx in dataset) to 10/2020 (end of follow-up). Tx sequences were identified and grouped to enable outcomes analyses. Data for 4 select groups (grp) are presented: grp 1 (1L CDK4 & 6i to 2L CDK4 & 6i), grp 2 (1L CDK4 & 6i to 2L non-CDK4 & 6i), grp 3 (2L CDK4 & 6i to 3L CDK4 & 6i), grp 4 (2L CDK4 & 6i to 3L non- CDK4 & 6i). Progression-free survival (PFS) from regimen start date to disease progression or death was analyzed by line using Kaplan-Meier method; pts were censored on the start date of the subsequent tx or end of follow-up if a progression event was not reported. Pts were characterized as having primary or secondary endocrine resistance per ESMO guidelines, if applicable. Pt characteristics at initiation of 1st CDK4 & 6i and median PFS are summarized descriptively. Results: Of 690pts, the majority were white (n=555, 80%), had a median age of 61yrs (range 26-86) and were treated in community oncology practices (80%) in southern US (47%). Most pt characteristics between grp 1 vs grp 2 were not statistically different except for pts participating in clinical trials [grp 1 (n=3; 2%) vs grp 2 (n=12; 13%)]. Pts in grp 4 were younger than grp 3, with a median age of 60 and 67yrs, respectively (p<0.05). In the overall cohort, the most prevalent tx seq grp was 1L CDK4 & 6i followed by 2L CDK4 & 6i (n=165). There was significant treatment regimen heterogeneity across all grps, with the most frequent being 1L palbociclib/AI followed by 2L abemaciclib/fulvestrant received by 26 (16%) pts. Abemaciclib was prevalent in 1L (n=92; 13%), 2L (n= 204; 30%), 3L (n=122; 18%), ≥4L (n=344; 50%). Pts receiving seq CDK4 & 6i experienced a substantial PFS benefit in the subsequent line (grp 1: 17mo; grp 3: 11mo), while pts in non-seq grps experienced a numerically lower PFS from the non-CDK4 & 6i tx in the subsequent line (grp 2: 8mo; grp 4: 8mo). Median PFS for each grp is described in Table 1. Results of cox proportional hazards models will be presented.Conclusions: Seq CDK4 & 6i appears to deliver substantial 2L PFS in pts who had a meaningful PFS on 1L CDK4 & 6i. These results appear consistent for pts receiving 3L CDK4 & 6i who had a meaningful PFS to 2L CDK4 & 6i. While most pts received 1L CDK4 & 6i to 2L CDK4 & 6i, there was marked tx heterogeneity across all seqs in this predominantly community oncology sample, reinforcing the continued lack of consensus on this topic. While these results are hypothesis generating, these data serve as further rationale for additional prospective and retrospective studies evaluating the potential utilization and outcomes of CDK4 & 6i, after progression on a previous CDK4 & 6i.Table 1.Grp 11L CDK4 & 6i to 2L CDK4 & 6i n=165Grp 21L CDK4 & 6ito 2L non-CDK4 & 6i n=94Grp 32L CDK4 & 6i to 3L CDK4 & 6i n=115Grp 42L CDK4 & 6i to 3L non-CDK4 & 6i n=121Line 1No. of Events/Pts78/16572/94Median (m)18.459.8095% CI[15.0, 23.2][6.4, 14.2]Line 2No. of Events/Pts55/16540/9455/11587/121Median (m)17.308.3917.308.2995% CI[9.8, 33.4][5.9, 10.5][12.1, 21.0][6.2, 9.9]Line 3No. of Events/Pts46/11557/121Median (m)11.227.8695% CI[6.8, 14.0][5.5, 11.3]Citation Format: Kevin M Kalinsky, Megan Kruse, Emily Nash Smyth, Claudia M Guimaraes, Santosh Gautam, Alnecia R Nisbett, Maxine D Fisher, Zhanglin Lin Cui, Lee Bowman. Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 and 6i for HR+, HER2- MBC in the real world [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-18-37.

10 October 2025 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
CTCarlyn Tan
Carlyn Tan
JHJennifer S. Harper
Jennifer S. Harper
SGSantosh Gautam
Santosh Gautam
AFAlex Z. Fu
Alex Z. Fu
VKVipin Khare
Vipin Khare
SKShuchita Kaila
Shuchita Kaila
Bortezomib (V)-based regimens are standard first-line treatment options for multiple myeloma (MM), an incurable plasma cell malignancy. A common adverse reaction in patients receiving V is treatment-emergent peripheral neuropathy (TEPN), which can negatively impact patients' quality of life and increase healthcare burden. We applied a line-of-therapy algorithm to Optum's de-identified Clinformatics® Data Mart Database. Patients were grouped into V-based versus non-V-based regimens, and 1:1 matching was applied. After matching, baseline demographics and clinical characteristics were similar between groups, including mean age (V-based, 74.5; non-V-based, 74.8 years) and males (V-based, 53.7%; non-V-based, 50.9%). TEPN was observed in 24% of patients in the V-based group versus 9% in the non-V-based group. The TEPN incidence rate was significantly higher in the V-based group versus non-V-based group (46.0 vs. 15.8 per person-years, p < 0.0001). Identifying therapies associated with lower TEPN incidence can inform MM treatment choices.